Each month, pharmacists and pharmacy technicians at Premier® member institutions are invited to participate in live, knowledge-based, continuing pharmacy education (CPE) activities. The CPE activities are provided as teleconferences/webinars on topics that are based on member needs assessment surveys, new guidelines or regulation updates, and new findings in medical literature. **All CPE offerings are fully funded by Premier and are free to Premier members.** Please post this CPE calendar in your pharmacy department so that all staff can view the CPE program offerings.

**Please Note:** Pharmacy Practice and Antimicrobial Stewardship Forums include accredited CPE activities, and if there is time, also include discussion topics led by Forum Co-Chairs.

The 2024 Co-Chairs of the Pharmacy Practice Forums are Marcia Curran, PharmD, BCPS, Union Hospital, Terre Haute, IN and Gregory Fakelmann, PharmD, MPH, CPh, Baptist Health System, Louisville, KY.

The 2024 Co-Chairs of the Antimicrobial Stewardship Forums are Amy Fabian, PharmD, BCPS, BCIDP, University Hospital St. John Medical Center, Westlake, OH and Shaina Doyen, PharmD, BCIDP, Baptist Health System, Louisville, KY.

### January

#### 10 Wednesday

**Outsourcing to 503Bs: Ingredients, Methods and Strategies**

**Noon – 1:00 p.m. EDT**

**Speaker:** Kevin N. Hansen, PharmD, MS, BCSCP, Director, 503B Program, Pharmacy, Premier, Inc.

**UAN:** 0122-0000-24-002-L07-P/T (Compounding CE)

0.1 CEU; 1 contact hour

**Pharmacist and Pharmacy Technician Objectives**

- Outline FDA guidance on the use of bulk drug substances as ingredients for 503B preparations
- Identify preparations that may be considered an ‘essentially copy’ of a conventionally manufactured product
- Compare the sterility assurance associated with various sterilization methods used for compounded sterile preparations
- Describe strategies for maintaining a stable supply chain of ready-to-administer medications through implementing USP <797> Category 3 and IV robotics

#### 30 Tuesday

**Adalimumab-SOS: Navigating the Market Entry of Adalimumab Biosimilars in the US**

**Noon – 1:00 p.m. EDT**

**Speaker:** Stefanie Cisek, PharmD, BCACP, Clinical Pharmacist – Inflammatory, Specialty Medicine – Clinical Team Lead, Northwestern Medicine, Chicago, IL

**UAN:** 0122-0000-24-004-L01-P/T

0.1 CEU; 1 contact hour

**Pharmacist Objectives**

- Review definitions pertaining to biologics and biosimilars, including interchangeability
- Compare the available adalimumab products
- Highlight opportunities for health system-based specialty pharmacies (HSSPs) to prepare for the launch of numerous adalimumab biosimilars that have come to market
- Describe the current and projected payor landscape for coverage of adalimumab products.
- Identify strategies for HSSPs to consider when selecting if/when an adalimumab biosimilar is appropriate

**Pharmacy Technician Objectives**

- Review definitions pertaining to biologics and biosimilars, including interchangeability
- Recognize the available adalimumab products
- List distinguishing factors among adalimumab products
- Identify areas of specialty pharmacy workflow that may be impacted by the launch of numerous adalimumab biosimilars that have come to market
<table>
<thead>
<tr>
<th>Date</th>
<th>Day</th>
<th>Event Title</th>
<th>Time</th>
<th>Speaker Details</th>
<th>UAN Code</th>
<th>CE Hours</th>
<th>Contact Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>07</td>
<td>Wednesday</td>
<td>NHSN Antibiotic Use Option Data: Implementation and Strategies for Use</td>
<td>Noon – 1:00 p.m. EST</td>
<td>Christopher Evans, PharmD, Pharmacist, Healthcare-Associated Infections and Antimicrobial Resistance Program, Tennessee Department of Health, Nashville, TN</td>
<td>0122-0000-24-005-L04-P/T</td>
<td>0.1 CEU</td>
<td>1 contact hour</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacists Objectives</td>
<td></td>
<td>• Explain the importance of antibiotic use reporting into the NHSN AUR Module</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Describe the necessary steps required for NHSN AU Option reporting</td>
<td></td>
<td>• Describe how to analyze and interpret data, including antibiotic use and Standardized Antibiotic Administration Ratio, available within the NHSN AU Option</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Provide examples of antibiotic use driving stewardship action</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacy Technician Objectives</td>
<td></td>
<td>• Explain the importance of antibiotic use reporting into the NHSN AUR Module</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Describe the necessary steps required for NHSN AU Option reporting</td>
<td></td>
<td>• Provide examples of antibiotic use driving stewardship action</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Tuesday</td>
<td>Medication Management of Parkinson’s Disease (PD) and Sequalae</td>
<td>Noon – 1:00 p.m. EST</td>
<td>Jacquelyn L. Bainbridge, B.S. Pharm, PharmD, FCCP, MSCS, FAES, Professor, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, Professor, Department of Neurology, Anschutz Medical Campus, University of Colorado, Aurora, CO</td>
<td>0122-0000-24-006-L01-P/T (Pharmacy Law CE)</td>
<td>0.1 CEU</td>
<td>1 contact hour</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacist Objectives</td>
<td></td>
<td>• Identify the clinical features of Parkinson’s Disease (PD) on physical examination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Describe the mechanisms of action of medications used for treatment of PD</td>
<td></td>
<td>• Recognize potential side effects of medications used for treatment of PD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Discuss common comorbid conditions and their treatment in PD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacy Technician Objectives</td>
<td></td>
<td>• Identify the clinical features of Parkinson’s Disease (PD) on physical examination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Describe the mechanisms of action of medications used for treatment of PD</td>
<td></td>
<td>• List three potential side effects of medications used for the treatment of Parkinson’s disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Name drugs used for management of Parkinson’s disease psychosis (PDP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### March

<table>
<thead>
<tr>
<th>Date</th>
<th>Day</th>
<th>Event</th>
<th>Time</th>
<th>Speaker</th>
<th>UAN</th>
<th>Pharmacist and Pharmacy Technician Objectives</th>
</tr>
</thead>
</table>
| 7    | Thursday | What's New with New Technology Add-On Payments?                       | Noon – 1:00 p.m. EST | Alison Schlang, PharmD, MBA, BCPS, FACHE, Director Advisory Services, Pharmacy, Premier, Inc. | 0122-0000-24-011-L04-P/T (Pharmacy Administration CE) | - Describe the history and current state of the New Technology Add-On Payment (NTAP) program  
- Outline coding and billing requirements for NTAPs  
- Identify opportunities to avoid revenue leakage related to NTAP and to address missed revenue |
| 20   | Wednesday | What Lies Ahead – A Look at the Biosimilar, Infectious Diseases and Specialty/Oncology Drug Pipeline in 2024-2025 | Noon – 1:00 p.m. EST | Liya Davydov, PharmD, BCPS, BCGP, Senior Director, Clinical Pharmacy Services, Continuum of Care, Premier, Inc. | 0122-0000-24-008-L01-P/T | - Identify biosimilar agents that have been recently approved, rejected or currently under regulatory review  
- List various reimbursement models/strategies for biosimilars  
- Identify notable agents that have been recently approved, rejected, in late stages of development or under regulatory review for infectious diseases indications  
- Identify specialty drugs currently under regulatory review for select indications  
- List oral and parenteral oncology agents currently under regulatory review for various cancers |
Sustaining Antimicrobial Stewardship Strategies in Suspected Sepsis

Noon – 1:00 p.m. EDT

Speaker: Jeffrey Pearson, PharmD, BCIDP, Advanced Practice Pharmacy Specialist, Infectious Diseases, PGY2 Infectious Diseases Pharmacy Residency Program Director, Brigham and Women’s Hospital, Boston, MA

UAN: 0122-0000-24-009-L01-P/T

0.1 CEU; 1 contact hour

Pharmacist and Pharmacy Technician Objectives

- Review Surviving Sepsis Campaign infection-related recommendations
- Discuss Centers for Medicare & Medicaid Services (CMS) sepsis requirements
- Describe antimicrobial stewardship strategies in critically ill patients presenting to the emergency room with sepsis or septic shock
- Describe antimicrobial stewardship strategies in patients recovering from sepsis or septic shock

Buprenorphine in the Management of Opioid Use Disorder (OUD): Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies

Noon – 1:00 p.m. EDT

Speaker: Michael Biglow, PharmD, BCPS, BCPP, Clinical Manager, Inpatient Pharmacy Services, Presbyterian Healthcare Services, Albuquerque, NM

UAN: 0122-0000-24-010-L08-P/T (Pain Management)

0.1 CEU; 1 contact hour

Pharmacist and Pharmacy Technician Objectives

- Review the unique properties and advantages of buprenorphine in the management of OUD
- Analyze novel dosing strategies for induction of high-risk patients
- Discuss the potential impact of the MAT Act (i.e. removal of the DATA 200 waiver) on patient access to buprenorphine
- Evaluate patient-specific parameters when considering long-acting injectable formulations
- Develop management strategies for use of buprenorphine in special populations (e.g. pediatrics, obstetrics)
## May

### 1 Wednesday

**Pharmacy Considerations for the Optimal Utilization of T-cell Engaging Bispecific Antibodies for Hematologic Malignancies**

**Noon – 1:00 p.m. EDT**

**Speaker:** Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, Clinical Oncology Pharmacy Manager, Pharmacy Services - Levine Cancer Institute, Atrium Health, Charlotte, NC

**UAN:** 0122-0000-24-007-L01-P/T

0.1 CEU; 1 contact hour

**Pharmacist and Pharmacy Technician Objectives**

- Review the pharmacology and indications of recently approved T-cell engaging bispecific antibodies for the treatment of hematologic malignancies
- Evaluate efficacy data supporting the approval of bispecific antibodies for multiple myeloma and lymphomas
- Describe supportive care strategies to prevent and manage adverse events associated with bispecific antibodies
- Define best practices for pharmacies to overcome administration and operational challenges associated with bispecific antibodies

### 22 Wednesday

**Cultivating an Inclusive Culture: Managing Difficult Co-Workers Including Yourself**

**Noon – 1:00 p.m. EDT**

**Speakers:** Kevin N. Hansen, PharmD, MS, BCSCP, Director, 503B Program, Pharmacy, Premier, Inc.

Robert P. Granko, BS Pharm, PharmD, MBA, FASHP, FNCP, Senior Director of Pharmacy, PennState Health, Hershey Medical Center, Hershey, PA

**UAN:** 0122-0000-24-012-L99-P/T (Application-based CE)

0.1 CEU; 1 contact hour

**Pharmacist and Pharmacy Technician Objectives**

- Identify the categories of difficult and disruptive people.
- Match distinct behaviors and characteristics of difficult and disruptive coworkers.
- Summarize strategies for effectively dealing with each type of difficult or disruptive co-worker.
- Given a case scenario involving difficult or disruptive behavior, determine the best approach to manage the outcome.
### June 4 Wednesday

**Therapeutics for Respiratory Syncytial Virus: How Far We’ve Come**

**Noon – 1:00 p.m. EDT**

**Speaker:** Christine R. Lockowitz, PharmD, BCIDP, Pediatric Infectious Diseases Clinical Pharmacy Specialist, Co-Director, SLCH Antimicrobial Stewardship Program, St. Louis Children's Hospital, St. Louis, MO

**UAN:** 0122-0000-24-013-L01-P/T

0.1 CEU; 1 contact hour

**Pharmacist Objectives**
- Describe the risk factors associated with severe RSV illness
- Recall the complications of RSV illness in both children and adults
- Review the available safety and efficacy data for therapeutics in the prevention of RSV in both children and adults
- Identify which patients qualify for an RSV vaccine
- Discuss the approach to preventing RSV in infants

**Pharmacy Technician Objectives**
- Discuss the prevalence and seasonality of respiratory syncytial virus (RSV)
- Recognize the risk factors for severe RSV illness
- Recall the available therapeutics for the prevention of RSV in both children and adults
- Explain the dosing and administration of available therapeutics for the prevention of RSV

---

### June 24 Wednesday

**Protecting Our Little Ones! Reducing Medication Errors in Neonates and Pediatrics**

**Noon – 1:00 p.m. EDT**

**Speaker:** Judith Scala, PharmD, BCPPS, Pediatric Pharmacy Clinical Coordinator, PGY2 Pediatric Pharmacy Residency Program Director, Department of Pharmaceutical Services, Saint Peter's University Hospital, New Brunswick, NJ

**UAN:** 0122-0000-24-014-L05-P/T (Patient Safety)

0.1 CEU; 1 contact hour

**Pharmacist Objectives**
- Recall the incidence, types, and risk factors for pediatric medication errors
- Explain the Joint Commission Sentinel Event Alert, Issue 39, “Preventing Pediatric Medication Errors”
- Describe the Institute for Safe Medication Practices’ (ISMP) best practices when prescribing, preparing, dispensing, and administering pediatric medications
- Define Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List

**Pharmacy Technician Objectives**
- List the risk factors for pediatric medications errors
- Describe the Institute for Safe Medication Practices’ (ISMP) best practices when prescribing, preparing, dispensing, and administering pediatric medications
- List the requirements for pediatric medication orders
- Define Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List
Each participant must create an account on the Premier® CE website.

To get credit posted to their CPE Monitor account, participants must do the following:

1. **Register** for the activity on the Premier® CE website.
2. **Take** the pre-test.
3. **Participate** in the CE activity.
4. **Complete** the post-test and evaluation on the CE website within 45 days of the event.

[Click here](#) to view CE webinar system requirements for the learner to complete the online activity, including the internet browser(s) supported and minimum versions of each, and the minimum memory, storage, processor, and internet.

**CONTACTS:**

Jerry Frazier, PharmD ([jerry_frazier@premierinc.com](mailto:jerry_frazier@premierinc.com))
Brenda Cora ([brenda_cora@premierinc.com](mailto:brenda_cora@premierinc.com))

Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. These CE activities are free of charge to Premier members. CE participation will be provided to CPE Monitor within 45 days of the CE activity, upon verification of participation in the educational program, successful completion of the learning assessment and speaker evaluation. NABP e-profile ID number and birthdate (MMDD) must be provided by participants in order to receive CE credit.